Abied(纳斯达克：aBMD)报道始于StockNews.com

StockNews.com initiated coverage on shares of Abiomed (NASDAQ:ABMD – Get Rating) in a research report released on Tuesday morning. The firm issued a hold rating on the medical equipment provider's stock.

Other equities research analysts have also recently issued reports about the stock. Piper Sandler cut shares of Abiomed from an overweight rating to a neutral rating and boosted their price target for the stock from $350.00 to $380.00 in a research report on Tuesday, November 1st. Morgan Stanley upgraded Abiomed from an underweight rating to an equal weight rating and boosted their price objective for the stock from $235.00 to $380.00 in a report on Wednesday, November 2nd. Mizuho assumed coverage on Abiomed in a report on Wednesday, October 12th. They set a buy rating and a $300.00 price objective on the stock. Deutsche Bank Aktiengesellschaft downgraded Abiomed from a buy rating to a hold rating and boosted their price objective for the stock from $355.00 to $388.00 in a report on Wednesday, November 2nd. Finally, William Blair downgraded Abiomed from an outperform rating to a market perform rating in a report on Tuesday, November 1st. Seven analysts have rated the stock with a hold rating and one has given a buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of Hold and a consensus price target of $350.50.

Get Abiomed alerts:

Abiomed Price Performance

Shares of NASDAQ ABMD opened at $381.02 on Tuesday. Abiomed has a fifty-two week low of $219.85 and a fifty-two week high of $381.99. The firm's 50-day simple moving average is $373.21 and its 200 day simple moving average is $302.48. The stock has a market cap of $17.18 billion, a P/E ratio of 65.47, a P/E/G ratio of 3.33 and a beta of 1.40.

Abiomed (NASDAQ:ABMD – Get Rating) last issued its quarterly earnings results on Tuesday, November 1st. The medical equipment provider reported $1.30 EPS for the quarter, topping the consensus estimate of $1.05 by $0.25. Abiomed had a net margin of 24.84% and a return on equity of 14.77%. The firm had revenue of $265.92 million for the quarter, compared to analysts' expectations of $273.30 million. On average, sell-side analysts anticipate that Abiomed will post 4.58 earnings per share for the current fiscal year.

Insider Buying and Selling at Abiomed

In other Abiomed news, Director Paul Thomas sold 1,000 shares of Abiomed stock in a transaction dated Tuesday, November 1st. The stock was sold at an average price of $379.38, for a total transaction of $379,380.00. Following the transaction, the director now owns 6,357 shares of the company's stock, valued at approximately $2,411,718.66. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In other Abiomed news, Director Paul Thomas sold 1,000 shares of Abiomed stock in a transaction dated Tuesday, November 1st. The stock was sold at an average price of $379.38, for a total transaction of $379,380.00. Following the transaction, the director now owns 6,357 shares of the company's stock, valued at approximately $2,411,718.66. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP Marc A. Began sold 2,000 shares of Abiomed stock in a transaction dated Friday, November 4th. The shares were sold at an average price of $373.71, for a total value of $747,420.00. Following the transaction, the vice president now directly owns 13,785 shares in the company, valued at approximately $5,151,592.35. The disclosure for this sale can be found here. Insiders have sold a total of 6,544 shares of company stock valued at $2,468,594 in the last 90 days. 2.50% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Abiomed

Large investors have recently made changes to their positions in the company. Sugarloaf Wealth Management LLC bought a new stake in shares of Abiomed in the 2nd quarter valued at approximately $25,000. TCI Wealth Advisors Inc. grew its stake in shares of Abiomed by 420.8% in the 3rd quarter. TCI Wealth Advisors Inc. now owns 125 shares of the medical equipment provider's stock valued at $31,000 after buying an additional 101 shares in the last quarter. Janiczek Wealth Management LLC grew its stake in shares of Abiomed by 730.8% in the 2nd quarter. Janiczek Wealth Management LLC now owns 108 shares of the medical equipment provider's stock valued at $32,000 after buying an additional 95 shares in the last quarter. Parkside Financial Bank & Trust grew its stake in shares of Abiomed by 96.5% in the 1st quarter. Parkside Financial Bank & Trust now owns 112 shares of the medical equipment provider's stock valued at $38,000 after buying an additional 55 shares in the last quarter. Finally, Ellevest Inc. grew its stake in shares of Abiomed by 57.8% in the 2nd quarter. Ellevest Inc. now owns 161 shares of the medical equipment provider's stock valued at $40,000 after buying an additional 59 shares in the last quarter. Institutional investors own 94.48% of the company's stock.

Abiomed Company Profile

(Get Rating)

Abiomed, Inc engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5, a percutaneous micro heart pump with integrated motor and sensors; and Impella CP, a device for use by interventional cardiologists to support patients in the cath lab, as well as by cardiac surgeons in the heart surgery suite.

Featured Articles

• Get a free copy of the StockNews.com research report on Abiomed (ABMD)
• Can Chip Gear Maker Lam Continue Its Rally As Earnings Slow?
• Bed Bath & Beyond Stock Crumbles 24% On Possible Bankruptcy News
• Why Is Kraft Heinz Moving Higher
• What will this mean for the Devon Energy stock price this year?
• Nio Stock, Is This The Bottom ?

Receive News & Ratings for Abiomed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abiomed and related companies with MarketBeat.com's FREE daily email newsletter.